“Justices to side with generic drugmakers in patent spat, attorneys predict”

Jimmy Azadian quoted in the Westlaw article “Justices to side with generic drugmakers in patent spat, attorneys predict.” The article discusses a pending U.S. Supreme Court decision involving inducement liability and “skinny labels” in the pharmaceutical industry, with attorneys closely watching how the Court will interpret pleading standards for patent infringement claims. Many observers believe the justices may avoid creating a broad new legal standard and instead focus narrowly on applying existing plausibility standards under Twombly and Iqbal, while the outcome could still significantly affect how future inducement cases are litigated. The case carries major implications for generic drug manufacturers, particularly regarding whether companies can avoid liability by carving patented uses out of their labels.